Zymeworks (ZYME) has put its antibody drug conjugate pipeline in the spotlight, announcing six new preclinical data posters and an upcoming Phase 1 ZW191 oral presentation at the AACR Annual Meeting 2026.

The recent AACR pipeline update and new executive appointments come after a strong run in the stock, with a 30 day share price return of 19.21% and a 1 year total shareholder return of 141.11%. However, the 5 year total shareholder return of a 1.94% loss shows how recent momentum contrasts with a softer longer term picture.

If Zymeworks’ recent move has you thinking about what else is out there in healthcare, it could be worth scanning other oncology and biotech names through 36 healthcare AI stocks.

With Zymeworks trading at US$27.80, a 37% intrinsic discount and a 44% gap to the average analyst target suggest upside on paper. However, after a 141% 1-year return, the question is whether there is still a genuine opportunity here or if future growth is already priced in.

Most Popular Narrative: 30.6% Undervalued

Against the last close at $27.80, the most followed narrative points to a fair value of about $40.08, putting a clear gap between price and modeled worth.

The analysts have a consensus price target of $40.08 for Zymeworks based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $31.0.

Curious what has to happen for that gap to close? The narrative leans on faster revenue expansion, a swing from losses to profits, and a rich future earnings multiple.

Result: Fair Value of $40.08 (UNDERVALUED)

However, there is still real execution risk with heavy dependence on milestone and royalty payments, and key trials like HERIZON GEA-01 and ZW191 carrying clear binary outcomes.

Next Steps

With all this optimism and risk in the mix, it helps to look under the hood yourself and decide if the rewards stack up. To see what is getting investors excited and weigh those potential upsides against your own expectations, take a closer look at the 3 key rewards.

Looking for more investment ideas?

If Zymeworks is on your radar, do not stop there. Widen your watchlist with a few focused stock ideas that could sharpen your next investing move.

• Spot potential value opportunities early by checking companies highlighted in the screener containing 23 high quality undiscovered gems.
• Prioritise financial resilience by scanning stocks in the solid balance sheet and fundamentals stocks screener (42 results).
• Target dependable income streams by reviewing companies featured as 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.